Headlines about Dendreon (NASDAQ:DNDN) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dendreon earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 43.6027509154388 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
WARNING: “Dendreon (DNDN) Receives Media Sentiment Rating of 0.16” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2798491/dendreon-dndn-receives-media-sentiment-rating-of-0-16.html.
Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers.
Receive News & Ratings for Dendreon Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dendreon Co. and related companies with MarketBeat.com's FREE daily email newsletter.